About Ischemix
Ischemix is a company based in Grafton (United States) founded in 2006. Ischemix has raised $6.6 million across 2 funding rounds from investors including U.S Army. Ischemix offers products and services including CMX-2043. Ischemix operates in a competitive market with competitors including Tonix Pharma, Edge Therapeutics, veriNOS pharmaceuticals, Neuraptive and Proniras, among others.
- Headquarter Grafton, United States
- SectorsHealthcare
- Phone•••• ••••
- Website ischemix.com
- Social LinkedIn X
- Legal Name Ischemix, Inc.
- Total Equity Funding$6.6M (USD)
in 2 rounds
- Latest Funding Round$2.9M (USD), Grant
Jul 2021
- Investors
Products & Services of Ischemix
Ischemix offers a comprehensive portfolio of products and services, including CMX-2043.
Cytoprotective drug for treating traumatic brain injury effectively.
Funding Insights of Ischemix
Ischemix has successfully raised a total of $6.6M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $2.9 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $6.6M
- Total Rounds 2
- Last Round Grant — $2.9M
- First Round $6.6M
(Jun 2014)
- Investors Count 1
All 2 funding rounds of Ischemix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2021 | $2.9M | Grant | – | – | |
| Jun 2014 | $6.6M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Ischemix
Ischemix has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include U.S Army.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Land-based military forces are organized and deployed for national defense. | 1775 | army.mil | - |
Investor details for Ischemix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Ischemix
3 dated milestones of Ischemix across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Ischemix is founded.
- Funding First funding round of $6.6M.
- Funding Latest funding round, Grant, of $2.9M.
Competitors of Ischemix
Ischemix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tonix Pharma, Edge Therapeutics, veriNOS pharmaceuticals, Neuraptive and Proniras, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tonixpharma.com | 2007 | New York, United States | $4.45M | 117 | Next-generation medicines for CNS and immunological disorders are developed. | |
| edgetherapeutics.com | 2009 | New Providence, United States | $164.73M | 26 | Novel therapies for acute neurological conditions are developed and commercialized. | |
| verinos-pharma.com | 1998 | Wurzburg, Germany | $62.7M | – | Developer of therapeutics for retina and brain diseases | |
| neuraptive.com | 2016 | Lafayette, United States | $12.5M | – | Therapeutic solution for the repair of cut and crushed peripheral nerves. | |
| proniras.com | 2018 | Seattle, United States | $11.23M | 2 | Small molecules are developed for seizures and brain injury treatment. | |
| renetx.com | 2010 | New Haven, United States | $13.42M | – | First-in-class therapeutics for CNS injuries are developed by the company. | |
| freeoxbiotech.com | 2017 | Barcelona, Spain | $572,841 | – | Therapies for ischaemic stroke treatment are being developed. | |
| neurexistherapeutics.com | 2020 | Aurora, United States | $605,000 | – | Neuroprotective therapeutic peptides are developed for brain disorder treatment. |
Detailed competitors of Ischemix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ischemix
Websites that share an audience with Ischemix (ischemix.com).
Websites whose visitors overlap most with Ischemix. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| facebook.com | 100% | 12.1B | #3 | View details |
Latest news on Ischemix
Complete news archive for Ischemix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Ischemix
10 companies that operate in the same segment as Ischemix (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Ischemix
Ischemix was founded in 2006 and raised its 1st funding round 8 years after it was founded.
Ischemix is headquartered in Grafton, United States.
Ischemix is a funded company, having raised a total of $6.6M across 2 funding rounds to date. The company's 1st funding round was a Series A of $6.6M, raised on Jun 2014.
Ischemix was founded in 2006 and is based in Grafton, United States. Focus is placed on the biotechnology sector, where cytoprotective therapies for serious neurological conditions, including traumatic brain injury, are advanced. The lead candidate, CMX-2043, remains in preclinical trials, with activation of protein kinase B achieved through the phosphatidylinositide 3-kinase pathway to support treatment development.
Ischemix's top competitors include Tonix Pharma, Neuraptive and Neurexis Therapeutics.
Ischemix offers CMX-2043.
Ischemix has 1 investor. Key investors include U.S Army.
Ischemix operates through Ischemix, Inc..